We Treat Chronic Disease Caused By Microbiome Dysbiosis Our First Indication Affects 1 3 Us Population And Presents A $16B Annual Market Opportunity Beyond Thatwe Have Disrupted Drug Discovery With A Shorter Timeline To Marketfaster Investment Return And Relatively Small Up Front Investmentwith Our Lightning Rapid Carbohydrate Drug Discovery Platformwe Have A Pipeline Of Novel Mimos Targeting A Range Of Upper And Lower Gi Conditions
No conferences found for this company.
| Company Name | Isothrive Inc |
| Country |
Canada
|
| Address | N/A |
| Telephone | N/A |
| N/A |
